Greenwich LifeSciences opened lower at $15.80, compared with its previous close of $16.09. In the last trading session, the stock traded between $14.40 and $16.08. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Greenwich LifeSciences is now worth
$ 42.41
Resulting in a loss of
$ 57.59 (57.59%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.79 (-4.88%)
Day High
$16.08
Day Low
$14.40
Day Open
$15.80
Prev Close
$16.09
Volume
1,96,799
1W Return
-7.07%
1M Return
-13.99%
3M Return
-1.58%
6M Return
-36.57%
1Y Return
80.70%
Fundamentals
Market Cap ($ Mn)
225
PE Ratio
-
PB Ratio
73.93
PEG Ratio
-
ROE
-313.10%
ROCE
-317.53%
EPS (TTM)
$-0.27
Investment Returns
1 Week
-7.07%
1 Month
-13.99%
3 Months
-1.58%
6 Months
-36.57%
9 Months
-44.81%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
10Aug
Greenwich LifeSciences Extends Insider Lock-Up To January 31, 2027
Greenwich LifeSciences extends the 100% lock-up on insider shares to January 31, 2027, restricting sales by directors, officers, and pre-IPO investors. The Board retains discretion to modify terms for strategic or financial reasons, including implementing leak-out plans or 10b5-1 programs.
3mo ago
22Jul
Greenwich expands FLAMINGO-01 trial to UK sites
Greenwich LifeSciences received UK regulatory approval to expand its Phase III FLAMINGO-01 trial, adding 5-10 sites in collaboration with The Royal Marsden. The company expects Q2 2026 cash burn of $2 million, down from $4.7 million in Q1, with a cash balance of $8.9 million as of June 30, 2026. Preliminary data shows a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm.
3mo ago
22Jul
Greenwich LifeSciences price target raised to $69 by HC Wainwright
HC Wainwright & Co. analyst Yi Chen maintained a Buy rating for Greenwich LifeSciences and raised the price target to $69 from $50.
3mo ago
9Jul
Greenwich LifeSciences gains EMA approval for GP2 use in FLAMINGO-01
Greenwich LifeSciences has secured EMA approval to use commercially manufactured GP2 in its FLAMINGO-01 Phase III trial, enabling US and European sites to utilize a single commercial lot. The trial has screened over 1,300 patients, with preliminary data showing a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm.
